360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Pharmasset Inc

Type: Company

Name: Pharmasset Inc

Nationality: United States

Web Address: http://www.pharmasset.com/

First reported May 15 2013 - Updated May 15 2013 - 4 reports

Pharmasset Inc

Apelian is Achillion's first medical chief

Achillion Pharmaceuticals Inc. named David Apelian M.D. to be the New Haven drug-developer's first-ever chief medical officer.Apelian, who will be executive vice president, will oversee clinical development of Achillion's portfolio of compounds to treat ... [Published Hartford Business Journal - May 15 2013]

Entities: Pharmasset Inc, Schering-Plough Corp, GlobeImmune Inc, Achillion Pharmaceuticals Inc

First reported May 07 2013 - Updated May 08 2013 - 1 reports

Biotech firms evolve from targets to acquirers

(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) * Skyrocketing valuations quash talks * With financing available, many biotechs go it alone * Bankers expect steady flow of $1 bln to $5 bln pharma deals By Jessica ... [Published Sharenet - May 07 2013]

Entities: Biotechnology, Mergers & Acquisitions, Gilead Sciences Inc

First reported May 04 2013 - Updated May 04 2013 - 1 reports

ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!

- Reports Corner has added a new report " ". Please visit the link https://www.reportscorner.com/reports/15825/ENANTA-PHARMA---Debut-of-a-Star--2nd-in-the-Oral-IFN-free-HCV-Drug-Race!/Gilead entered the HCV race with the acquisition of Pharmasset in 2011 ... [Published Prlog - May 04 2013]

Entities: Enanta Pharmaceuticals Inc, Drugs, Pharmasset Inc, Sofosbuvir

First reported May 03 2013 - Updated May 04 2013 - 1 reports

Gilead Sciences climbs to all-time highs

NEW YORK -- Shares of Gilead Sciences Inc. rose to all-time highs Friday after the company reported its first-quarter results and new trial data for two of its experimental hepatitis C drugs.THE SPARK: Gilead posted its quarterly results after the market ... [Published Equities.com - May 03 2013]

Entities: Gilead Sciences Inc, Drugs, Hepatitis C, Sofosbuvir

First reported May 02 2013 - Updated May 03 2013 - 2 reports

Gilead profits surge 63%, but not where Wall Street expected

Gilead also reports more good news about hep C hopefulShareToolsGilead Sciences was in a position to say, "I told you so," when its first-quarter earnings fell a little short of Wall Street expectations Thursday. Profits were still up 63% even as sales ... [Published FiercePharma - May 03 2013]

Entities: Gilead Sciences Inc, Wall Street, Truvada, HIV/AIDS

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Gilead Sciences Inc

Gilead Misses on Earnings, Sales in 1Q - Analyst Blog

Gilead Sciences, Inc. ‘s ( GILD ) first quarter 2013 earnings (excluding special items but including stock option expense) of 45 cents per share missed the Zacks Consensus Estimate of 47 cents per share. Lower-than-expected revenues were responsible ... [Published Zacks.com - May 03 2013]

Entities: Gilead Sciences Inc, Athersys Inc, Research & Development

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Motley Fool

4 Bio Stocks to Buy Today

Casey is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.Bio stocks can be a gamble. When they fall, companies in this particular industry can fall hard, especially if the news ... [Published Motley Fool - May 01 2013]

Entities: Motley Fool, Bavituximab, Pharmasset Inc, Biosante Pharmaceuticals Inc

First reported Apr 28 2013 - Updated Apr 28 2013 - 1 reports

Docs may find stellar Gilead/Bristol-Myers hep C combo too good to ignore

What if you had a great combination of rival drugs that worked in 100% of patients but one of the companies involved refused to participate in the trials needed for an approval? If you're Gilead, the answer is to shun the competitor drug and stay focused ... [Published FierceBiotech - Apr 28 2013]

Entities: Bristol-Myers Squibb Company, Patient, Sofosbuvir, Genotype

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Moody's sees pick-up in pharmaceutical industry M&A in 2013

LONDON, April 23 (Reuters) - Cash-rich drug companies are likely to make more acquisitions in 2013 after a thin year for deals in 2012, ratings agency Moody's Investors Service said on Tuesday.In an review of the global sector reiterating a "stable" outlook, ... [Published Yahoo! UK and Ireland - Apr 23 2013]

Entities: Moody's Corporation, Acquisition, Mergers & Acquisitions

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

Biotechnology Draws Record Profit as Research Money Slows

Biotechnology companies worldwide boosted profit by 37 percent to a record $5.2 billion in 2012, partly by tempering growth in research-and-development spending, according to Ernst & Young. Drugmakers led by Amgen Inc. (AMGN)The record profit doesn’t ... [Published BusinessWeek - Apr 23 2013]

Entities: Biotechnology, Ernst & Young, Genentech Inc, Research & Development, Mergers & Acquisitions

First reported Apr 10 2013 - Updated Apr 10 2013 - 1 reports

Gilead files hepatitis C drug sofosbuvir in the US

Gilead Sciences has filed for US approval of its investigational oral hepatitis C drug sofosbuvir, a little ahead of expectations.The move, which had been scheduled for sometime in the second quarter, has shifted the group a big step closer to becoming ... [Published Pharma Times - Apr 10 2013]

Entities: Sofosbuvir, Gilead Sciences Inc, Hepatitis C

First reported Jan 25 2013 - Updated Jan 26 2013 - 1 reports

Morgan Stanley Adviser Dowd Charged With Pharmasset Tips - Bloomberg

Morgan Stanley Adviser Dowd Charged With Pharmasset Tips Bloomberg Former Morgan Stanley brokerage adviser Kevin L. Dowd, was charged with insider trading for tipping two friends ahead of Gilead Sciences Inc. (GILD)'s acquisition of Pharmasset Inc. ... [Published Bloomberg via Google News - Jan 25 2013]

Entities: Pharmasset Inc, Morgan Stanley & Co, Gilead Sciences Inc, Insider Trading

Quotes

...Amgen recently announced that it "will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago." Additional disclosure: I do not warrant the accuracy of any data provided in this article or in the referenced DCF spreadsheet...

Here's Why Amgen Shares Are Worth $117 To $126 Today [Published Seeking Alpha - May 18 2013]

"FIG. 3. Percentage of wild-type at 5282 position in HCV replicons before and after treatment with GS-7977, ribavirin, and a combination of GS-7977 and ribavirin in long-term passaging study (15-30 days)."

"Methods and Compositions for Treating Hepatitis C Virus" in. . . [Published Equities.com - May 15 2013]

More Content

sort by: Date \| Relevance
Here's Why Amgen Shares Are Worth $117 To $126 ... [Published Seeking Alpha - May 18 2013]
"Methods and Compositions for Treating Hepatiti... [Published Equities.com - May 15 2013]
Apelian is Achillion's first medical chief [Published Hartford Business Journal - May 15 2013]
Achillion Appoints CMO [Published Contract Pharma - May 15 2013]
Achillion Names Dr. David Apelian CMO [Published Benzinga.com - May 15 2013]
Achillion Appoints Dr. David Apelian as Chief M... [Published Morningstar.com - May 15 2013]
Gilead-Bristol Hepatitis C Drug Combo Cures All... [Published National AIDS Treatment Advocacy Project - May 14 2013]
Gilead's Hepatitis C Drug Sofosbuvir Offers Upside [Published Seeking Alpha - May 09 2013]
AHF Shareholder Advocates Challenge Gilead on D... [Published Business Wire - May 08 2013]
Biotech firms evolve from targets to acquirers [Published Sharenet - May 07 2013]
ENANTA PHARMA - Debut of a Star- 2nd in the Ora... [Published Prlog - May 04 2013]
Gilead Sciences climbs to all-time highs [Published Equities.com - May 03 2013]
Gilead profits surge 63%, but not where Wall St... [Published FiercePharma - May 03 2013]
Gilead Misses on Earnings, Sales in 1Q - Analys... [Published Zacks.com - May 03 2013]
GILEAD SCIENCES, INC.: Gilead Sciences Reports ... [Published 4 Traders - May 02 2013]
UPDATE: Gilead Sciences Reports Higher Sales, F... [Published Nasdaq - May 02 2013]
Gilead Sciences 1Q income climbs 63 percent [Published CNBC - May 02 2013]
Biogen Idec Inc. (BIIB), Celgene Corporation (C... [Published InsiderMonkey.com - May 01 2013]
4 Bio Stocks to Buy Today [Published Motley Fool - May 01 2013]
Celsus Therapeutics Appoints Fredric Price to B... [Published Citybizlist - Apr 30 2013]
Celsus Therapeutics Strengthens Board of Direct... [Published Individual.com - Apr 30 2013]
Successful Hep-C Combo May Elude Patients as Gi... [Published Washington Post - Apr 28 2013]
Docs may find stellar Gilead/Bristol-Myers hep ... [Published FierceBiotech - Apr 28 2013]
Gilead-Bristol Hepatitis C Drug Combo Cures 100... [Published Bloomberg - Apr 27 2013]
Biotechnology Draws Record Profit as Research M... [Published BusinessWeek - Apr 23 2013]
Moody's sees pick-up in pharmaceutical industry... [Published Yahoo! UK and Ireland - Apr 23 2013]
Gilead files hepatitis C drug sofosbuvir in the US [Published Pharma Times - Apr 10 2013]
Idenix Pharmaceuticals Announces Decision by th... [Published GlobeNewswire: Acquisitions News - Mar 22 2013]
Doylestown is home to a bustling biotech center [Published Philadelphia Inquirer - Mar 11 2013]
Large Pharma May Get Involved As Achillion Hep ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Feb 13 2013]

Blogs

sort by: Date \| Relevance
Morgan Stanley Adviser Charged With Insider Tra... [Published Here is the city - Business News - Jan 28 2013] Former Morgan Stanley brokerage adviser Kevin Dowd was charged with insider trading for tipping a friend ahead of Gilead Sciences’s $11bn acquisition of Pharmasset, U.S. prosecutors said.... read more > ...
Broker Charged With Conspiracy in Insider Case [Published Corruption Currents - Jan 25 2013] U.S. authorities have accused a former Morgan Stanley Smith Barney broker of tipping a childhood friend ahead of the $11 billion acquisition of Pharmasset Inc. two years ago in exchange for cash and a jet ski. ...
Pharma Deals North of $10 Billion Seen Returnin... [Published PharmaGossip - Jan 07 2013] Get ready for the return of the $10 billion-plus drug deal. Pharmaceutical companies including Pfizer Inc. (PFE) and Bristol- Myers Squibb Co. (BMY) have spent the last several years digesting earlier acquisitions, refocusing their product ...
Is Gilead Sciences Still a Buy After the Recent... [Published Wall St. Cheat Sheet - Dec 11 2012] With shares of Gilead Sciences ( NASDAQ:GILD ) trading at around $74.25, is it an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework : C – Catalyst for the Stock’s Movement ...
Deals of the Year M&A Nominee: BMS/Inhibitex [Published The IN VIVO Blog - Dec 04 2012] It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making solutions of the year. The categories are: M&A ...

Press Releases

sort by: Date \| Relevance
AHF Shareholder Advocates Challenge Gilead on D... [Published Business Wire - May 08 2013]
Idenix Pharmaceuticals Announces Decision by th... [Published GlobeNewswire: Acquisitions News - Mar 22 2013]